Expression of CXCR4 is an independent prognostic factor for overall survival and progression-free survival in patients with myelodysplastic syndrome

被引：10

作者：

Zhang, Yizhuo ^{[1
]}

Guo, Qing ^{[1
]}

Zhao, Haifeng ^{[1
]}

Zhao, Dandan ^{[2
]}

Wu, Xiaoxiong ^{[2
]}

Zhao, Weipeng ^{[1
]}

Wang, Yafei ^{[1
]}

Xia, Bing ^{[1
]}

Da, Wanming ^{[3
]}

机构：

[1] Tianjin Med Univ, Tianjin Canc Hosp & Inst, Dept Hematol, Tianjin 300060, Peoples R China

[2] Chinese Peoples Liberat Army Gen Hosp, Affiliated Hosp 1, Dept Hematol, Beijing, Peoples R China

[3] Gen Hosp Peoples Liberat Army, Dept Hematol, Beijing, Peoples R China

来源：

MEDICAL ONCOLOGY | 2013年 / 30卷 / 01期

基金：

中国国家自然科学基金;

关键词：

Myelodysplastic syndrome; CXCR4; Prognostic factor; WORLD-HEALTH-ORGANIZATION; CHEMOKINE RECEPTOR CXCR4; BONE-MARROW; SCORING SYSTEM; MUTATIONS; CLASSIFICATION; CANCER; METASTASIS; NEOPLASMS; AXIS;

D O I：

10.1007/s12032-012-0341-6

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

CXCR4 is the receptor of stromal cell-derived factor (SDF-1) and is expressed in many types of cancer cells. It also plays an important role in metastasis of malignant disease. In this study, we detected the expression of CXCR4 in 81 patients with myelodysplastic syndrome (MDS) by flow cytometry. We categorized MDS patients into the high-expression group and low-expression group according to CXCR4 mean florescence intensity ration thresholds. We showed that the high-expression group had a shorter overall survival time and shorter relapse-free survival time compared with those of the low-expression group (21.6 +/- 1.9 vs. 46.0 +/- 1.6 months, 17.0 +/- 1.9 vs. 42.5 +/- 2.1 months, respectively, P<0.05), and Cox regression showed that CXCR4 was an independent prognostic factor. We conclude that the expression of CXCR4 is a useful prognostic factor for patients with MDS.

引用

页数：4

共 22 条

[1]

Anke C, 2007, BLOOD, V109, P786

[2] The significance of cancer cell expression of the chemokine receptor CXCR4 [J].

Balkwill, F .

SEMINARS IN CANCER BIOLOGY, 2004, 14 (03) :171-179

[3] World Health Organization classification in combination with cytogenetic markers improves the prognostic stratification of patients with de novo primary myelodysplastic syndromes [J].

Bernasconi, Paolo ;

Klersy, Catherine ;

Boni, Marina ;

Cavigliano, Paola M. ;

Calatroni, Silvia ;

Giardini, Ilaria ;

Rocca, Barbara ;

Zappatore, Rita ;

Caresana, Marilena ;

Dambruoso, Irene ;

Lazzarino, Mario ;

Bernasconi, Carlo .

BRITISH JOURNAL OF HAEMATOLOGY, 2007, 137 (03) :193-205

[4] Chemokine receptor CXCR4 expression in breast cancer as a potential predictive marker of isolated tumor cells in bone marrow [J].

Cabioglu, N ;

Sahin, A ;

Doucet, M ;

Yavuz, E ;

Igci, A ;

Yildirim, EO ;

Aktas, E ;

Bilgic, S ;

Kiran, B ;

Deniz, G ;

Price, JE .

CLINICAL & EXPERIMENTAL METASTASIS, 2005, 22 (01) :39-46

[5] The roles of SDF-1/CXCR4 axis and its relationship with apoptosis in the myelodysplastic syndromes [J].

Chang Chunkang ;

Yang Rui ;

Xu Feng ;

Guo Juan ;

Zhang Xi ;

Wu Lingyun ;

Li Xiao ;

Wang Jianmin .

MEDICAL ONCOLOGY, 2011, 28 :S494-S500

[6] Clinical Relevance of Bone Marrow Fibrosis and CD34-Positive Cell Clusters in Primary Myelodysplastic Syndromes [J].

Della Porta, Matteo Giovanni ;

Malcovati, Luca ;

Boveri, Emanuela ;

Travaglino, Erica ;

Pietra, Daniela ;

Pascutto, Cristiana ;

Passamonti, Francesco ;

Invernizzi, Rosangela ;

Castello, Alessandro ;

Magrini, Umberto ;

Lazzarino, Mario ;

Cazzola, Mario .

JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (05) :754-762

[7] Refinement of the international prognostic scoring system (IPSS) by including LDH as an additional prognostic variable to improve risk assessment in patients with primary myelodysplastic syndromes (MDS) [J].

Germing, U ;

Hildebrandt, B ;

Pfeilstöcker, M ;

Nösslinger, T ;

Valent, P ;

Fonatsch, C ;

Lübbert, M ;

Haase, D ;

Steidl, C ;

Krieger, O ;

Stauder, R ;

Giagounidis, AAN ;

Strupp, C ;

Kündgen, A ;

Mueller, T ;

Haas, R ;

Gattermann, N ;

Aul, C .

LEUKEMIA, 2005, 19 (12) :2223-2231

[8] Tumor-cell homing to lymph nodes and bone marrow and CXCR4 expression in esophageal cancer [J].

Kaifi, JT ;

Yekebas, EF ;

Schurr, P ;

Obonyo, D ;

Wachowiak, R ;

Busch, P ;

Heinecke, A ;

Pantel, K ;

Izbicki, JR .

JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2005, 97 (24) :1840-1847

[9] Proposal for a new risk model in myelodysplastic syndrome that accounts for events not considered in the original International Prognostic Scoring System [J].

Kantarjian, Hagop ;

O'Brien, Susan ;

Ravandi, Farhad ;

Cortes, Jorge ;

Shan, Jianqin ;

Bennett, John M. ;

List, Alan ;

Fenaux, Pierre ;

Sanz, Guillermo ;

Issa, Jean-Pierre ;

Freireich, Emil J. ;

Garcia-Manero, Guillermo .

CANCER, 2008, 113 (06) :1351-1361

[10] Mutations of IDH1 and IDH2 genes in early and accelerated phases of myelodysplastic syndromes and MDS/myeloproliferative neoplasms [J].

Kosmider, O. ;

Gelsi-Boyer, V. ;

Slama, L. ;

Dreyfus, F. ;

Beyne-Rauzy, O. ;

Quesnel, B. ;

Hunault-Berger, M. ;

Slama, B. ;

Vey, N. ;

Lacombe, C. ;

Solary, E. ;

Birnbaum, D. ;

Bernard, O. A. ;

Fontenay, M. .

LEUKEMIA, 2010, 24 (05) :1094-1096

← 1 2 3 →